This study aimed to investigate the potential common targets, core active ingredients, and key signaling pathways of Yinchenhao Decoction combined with Lamivudine in the treatment of alcoholic liver disease (ALD) using network pharmacology and molecular docking, providing a theoretical basis for this integrative therapy. Active ingredients of Yinchenhao Decoction and Lamivudine targets were screened from the TCMSP and ChEMBL databases, while ALD-related targets were obtained from GeneCards, TTD, and DrugBank. Common targets were identified via Venny analysis, and a protein-protein interaction (PPI) network was constructed using STRING and Cytoscape. GO and KEGG enrichment analyses were performed with Metascape, and molecular docking was conducted using CB-Dock2. A total of 44 active compounds, 331 drug targets, and 1022 ALD targets were surveyed, yielding 44 overlapping targets. GO analysis indicated involvement in hormone response and nuclear receptor activity, while KEGG enrichment highlighted the "Chemical carcinogenesis–receptor activation" pathway. Molecular docking showed that aloe-emodin had the strongest binding affinity with IL-6 (–9.7), followed by lamivudine (–6.4), quercetin (–6.2), and kaempferol (–6.1). In conclusion, Yinchenhao Decoction combined with Lamivudine may treat ALD through multiple components acting on multiple targets and pathways, primarily via IL-6-driven inflammation control and nuclear receptor modulation, and IL-6 appears to be a useful biomarker for monitoring ALD progression under this combined therapy.

Shunhan Yang. Analysis of 'Component-Target-Pathway' and Mining of Potential Biomarkers for Yinchenhao Decoction Combined with Lamivudine in the Treatment of Alcoholic Liver Disease and Its Derived Disorders. International Journal of Frontiers in Medicine (2026), Vol. 8, Issue 2: 81-89. https://doi.org/10.25236/IJFM.2026.080210.

[1] Park, S.H. and D.J. Kim, Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies. Clin Mol Hepatol, 2020. 26(4): p. 652–661.

[2] Yao Y.Q., et al., Identification of constituents in vitro and blood-absorbed ingredients of protective effect on acute liver injury from Yin Chen Hao decoction based on UPLC-QTOF/MS. Acta Pharmaceutica Sinica, 2023. 58(5): p. 1173–1180.

[3] Wang, W.J., et al., Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol, 2019. 25(12): p. 1445–1456.

[4] Carvalho, J.R. and M. Verdelho Machado, New Insights About Albumin and Liver Disease. Ann Hepatol, 2018. 17(4): p. 547–560.

[5] Zhu, J.M., et al., ALB inhibits tumor cell proliferation and invasion by regulating immune microenvironment and endoplasmic reticulum stress in clear cell renal cell carcinoma. Biochim Biophys Acta Mol Basis Dis, 2025. 1871(3): p. 167672.

[6] Xu, C., et al., The role of TNF in metabolic disorders and liver diseases. Cytokine, 2025. 190: p. 156933.

[7] Kumar, R., S. Elangovan, and S.K. Asrani, Emerging therapeutic regimens as alternatives to glucocorticoids for severe alcohol-associated hepatitis: a comprehensive review. Clin Mol Hepatol, 2026. 32(2): p. 599–619.

[8] Salgüero, S., et al., Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. Sci Rep, 2020. 10(1): p. 10384.

[9] Liu, J., et al., Advancements in the understanding of mechanisms of the IL-6 family in relation to metabolic-associated fatty liver disease. Front Endocrinol (Lausanne), 2025. 16: p. 1642436.

[10] Kamal, R., et al., Quercetin in Oncology: A Phytochemical with Immense Therapeutic Potential. Curr Drug Targets, 2024. 25(11): p. 740–751.

[11] Chen, H., et al., Autophagy and exosomes coordinately mediate quercetin's protective effects on alcoholic liver disease. J Nutr Biochem, 2023. 116: p. 109332.

[12] Li, J., Z. Zhou, and Q. Zhou, Kaempferol inhibits lipid accumulation in alcoholic fatty liver disease through PRMT-1-mediated arginine methylation of SCD1. J Antibiot (Tokyo), 2025. 78(11): p. 686–696.

[13] Niziński, P., et al., Hepatoprotective Effect of Kaempferol-A Review. Molecules, 2025. 30(9).

[14] Li, W., M. Pan, and J. Tang, Aloe-emodin ameliorates non-alcoholic fatty liver disease by regulating the ZNRF3/Wnt/β-catenin axis and suppressing hepatic lipogenesis. Biochem Biophys Res Commun, 2026. 827: p. 153979.

[15] Huang, Juanjuan et al. “Effect of lamivudine and silymarin on liver fibrosis-relevant factors in HBV transgenic mice with alcohol drinking.” Journal of Central South University. Medical Sciences 42, 3 (2017): 257-263 .